LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 85

Search options

  1. Article ; Online: Impaired malin expression and interaction with partner proteins in Lafora disease.

    Skurat, Alexander V / Segvich, Dyann M / Contreras, Christopher J / Hu, Yueh-Chiang / Hurley, Thomas D / DePaoli-Roach, Anna A / Roach, Peter J

    The Journal of biological chemistry

    2024  Volume 300, Issue 5, Page(s) 107271

    Abstract: Lafora disease (LD) is an autosomal recessive myoclonus epilepsy with onset in the teenage years leading to death within a decade of onset. LD is characterized by the overaccumulation of hyperphosphorylated, poorly branched, insoluble, glycogen-like ... ...

    Abstract Lafora disease (LD) is an autosomal recessive myoclonus epilepsy with onset in the teenage years leading to death within a decade of onset. LD is characterized by the overaccumulation of hyperphosphorylated, poorly branched, insoluble, glycogen-like polymers called Lafora bodies. The disease is caused by mutations in either EPM2A, encoding laforin, a dual specificity phosphatase that dephosphorylates glycogen, or EMP2B, encoding malin, an E3-ubiquitin ligase. While glycogen is a widely accepted laforin substrate, substrates for malin have been difficult to identify partly due to the lack of malin antibodies able to detect malin in vivo. Here we describe a mouse model in which the malin gene is modified at the C-terminus to contain the c-myc tag sequence, making an expression of malin-myc readily detectable. Mass spectrometry analyses of immunoprecipitates using c-myc tag antibodies demonstrate that malin interacts with laforin and several glycogen-metabolizing enzymes. To investigate the role of laforin in these interactions we analyzed two additional mouse models: malin-myc/laforin knockout and malin-myc/LaforinCS, where laforin was either absent or the catalytic Cys was genomically mutated to Ser, respectively. The interaction of malin with partner proteins requires laforin but is not dependent on its catalytic activity or the presence of glycogen. Overall, the results demonstrate that laforin and malin form a complex in vivo, which stabilizes malin and enhances interaction with partner proteins to facilitate normal glycogen metabolism. They also provide insights into the development of LD and the rescue of the disease by the catalytically inactive phosphatase.
    Language English
    Publishing date 2024-04-07
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2997-x
    ISSN 1083-351X ; 0021-9258
    ISSN (online) 1083-351X
    ISSN 0021-9258
    DOI 10.1016/j.jbc.2024.107271
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Targeting Aldehyde Dehydrogenases to Eliminate Cancer Stem Cells in Gynecologic Malignancies.

    Muralikrishnan, Vaishnavi / Hurley, Thomas D / Nephew, Kenneth P

    Cancers

    2020  Volume 12, Issue 4

    Abstract: Gynecologic cancers cause over 600,000 deaths annually in women worldwide. The development of chemoresistance after initial rounds of chemotherapy contributes to tumor relapse and death due to gynecologic malignancies. In this regard, cancer stem cells ( ... ...

    Abstract Gynecologic cancers cause over 600,000 deaths annually in women worldwide. The development of chemoresistance after initial rounds of chemotherapy contributes to tumor relapse and death due to gynecologic malignancies. In this regard, cancer stem cells (CSCs), a subpopulation of stem cells with the ability to undergo self-renewal and clonal evolution, play a key role in tumor progression and drug resistance. Aldehyde dehydrogenases (ALDH) are a group of enzymes shown to be robust CSC markers in gynecologic and other malignancies. These enzymes also play functional roles in CSCs, including detoxification of aldehydes, scavenging of reactive oxygen species (ROS), and retinoic acid (RA) signaling, making ALDH an attractive therapeutic target in various clinical scenarios. In this review, we discuss the critical roles of the ALDH in driving stemness in different gynecologic malignancies. We review inhibitors of ALDH, both general and isoform-specific, which have been used to target CSCs in gynecologic cancers. Many of these inhibitors have been shown to be effective in preclinical models of gynecologic malignancies, supporting further development in the clinic. Furthermore, ALDH inhibitors, including 673A and CM037, synergize with chemotherapy to reduce tumor growth. Thus, ALDH-targeted therapies hold promise for improving patient outcomes in gynecologic malignancies.
    Language English
    Publishing date 2020-04-13
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2527080-1
    ISSN 2072-6694
    ISSN 2072-6694
    DOI 10.3390/cancers12040961
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Inhibition of the Aldehyde Dehydrogenase 1/2 Family by Psoralen and Coumarin Derivatives.

    Buchman, Cameron D / Hurley, Thomas D

    Journal of medicinal chemistry

    2017  Volume 60, Issue 6, Page(s) 2439–2455

    Abstract: Aldehyde dehydrogenase 2 (ALDH2), one of 19 ALDH superfamily members, catalyzes the ... ...

    Abstract Aldehyde dehydrogenase 2 (ALDH2), one of 19 ALDH superfamily members, catalyzes the NAD
    MeSH term(s) Aldehyde Dehydrogenase/antagonists & inhibitors ; Aldehyde Dehydrogenase/chemistry ; Aldehyde Dehydrogenase/metabolism ; Aldehyde Dehydrogenase, Mitochondrial/antagonists & inhibitors ; Aldehyde Dehydrogenase, Mitochondrial/metabolism ; Coumarins/chemistry ; Coumarins/pharmacology ; Drug Design ; Enzyme Inhibitors/chemistry ; Enzyme Inhibitors/pharmacology ; Ficusin/chemistry ; Ficusin/pharmacology ; Humans ; Isoenzymes/antagonists & inhibitors ; Isoenzymes/metabolism ; Molecular Docking Simulation ; Retinal Dehydrogenase/antagonists & inhibitors ; Retinal Dehydrogenase/chemistry ; Retinal Dehydrogenase/metabolism
    Chemical Substances Coumarins ; Enzyme Inhibitors ; Isoenzymes ; aldehyde dehydrogenase 1 (EC 1.2.1.-) ; ALDH1A1 protein, human (EC 1.2.1.3) ; Aldehyde Dehydrogenase (EC 1.2.1.3) ; Aldehyde Dehydrogenase, Mitochondrial (EC 1.2.1.3) ; ALDH1A2 protein, human (EC 1.2.1.36) ; Retinal Dehydrogenase (EC 1.2.1.36) ; Ficusin (KTZ7ZCN2EX)
    Language English
    Publishing date 2017-03-06
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, U.S. Gov't, Non-P.H.S.
    ZDB-ID 218133-2
    ISSN 1520-4804 ; 0022-2623
    ISSN (online) 1520-4804
    ISSN 0022-2623
    DOI 10.1021/acs.jmedchem.6b01825
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Development of substituted benzimidazoles as inhibitors of human aldehyde dehydrogenase 1A isoenzymes.

    Takahashi, Cyrus / Chtcherbinine, Mikhail / Huddle, Brandt C / Wilson, Michael W / Emmel, Timothy / Hohlman, Robert M / McGonigal, Stacy / Buckanovich, Ronald J / Larsen, Scott D / Hurley, Thomas D

    Chemico-biological interactions

    2024  Volume 391, Page(s) 110910

    Abstract: Aldehyde dehydrogenase 1A (ALDH1A) isoforms may be a useful target for overcoming chemotherapy resistance in high-grade serous ovarian cancer (HGSOC) and other solid tumor cancers. However, as different cancers express different ALDH1A isoforms, isoform ... ...

    Abstract Aldehyde dehydrogenase 1A (ALDH1A) isoforms may be a useful target for overcoming chemotherapy resistance in high-grade serous ovarian cancer (HGSOC) and other solid tumor cancers. However, as different cancers express different ALDH1A isoforms, isoform selective inhibitors may have a limited therapeutic scope. Furthermore, resistance to an ALDH1A isoform selective inhibitor could arise via induction of expression of other ALDH1A isoforms. As such, we have focused on the development of pan-ALDH1A inhibitors, rather than on ALDH1A isoform selective compounds. Herein, we report the development of a new group of pan-ALDH1A inhibitors to assess whether broad spectrum ALDH1A inhibition is an effective adjunct to chemotherapy in HGSOC. Optimization of the CM10 scaffold, aided by ALDH1A1 crystal structures, led to improved biochemical potencies, improved cellular efficacy as demonstrated by reduction in ALDEFLUOR signal in HGSOC cells, and substantial improvements in liver microsomal stability. Based on this work we identified two compounds 17 and 25 suitable for future in vivo proof of concept experiments.
    MeSH term(s) Humans ; Isoenzymes ; Aldehyde Dehydrogenase/metabolism ; Retinal Dehydrogenase/metabolism ; Aldehyde Oxidoreductases/metabolism ; Neoplasms
    Chemical Substances Isoenzymes ; Aldehyde Dehydrogenase (EC 1.2.1.3) ; Retinal Dehydrogenase (EC 1.2.1.36) ; Aldehyde Oxidoreductases (EC 1.2.-)
    Language English
    Publishing date 2024-02-15
    Publishing country Ireland
    Document type Journal Article
    ZDB-ID 218799-1
    ISSN 1872-7786 ; 0009-2797
    ISSN (online) 1872-7786
    ISSN 0009-2797
    DOI 10.1016/j.cbi.2024.110910
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Characterization of two distinct structural classes of selective aldehyde dehydrogenase 1A1 inhibitors.

    Morgan, Cynthia A / Hurley, Thomas D

    Journal of medicinal chemistry

    2015  Volume 58, Issue 4, Page(s) 1964–1975

    Abstract: Aldehyde dehydrogenases (ALDH) catalyze the irreversible oxidation of aldehydes to their corresponding carboxylic acid. Alterations in ALDH1A1 activity are associated with such diverse diseases as cancer, Parkinson's disease, obesity, and cataracts. ... ...

    Abstract Aldehyde dehydrogenases (ALDH) catalyze the irreversible oxidation of aldehydes to their corresponding carboxylic acid. Alterations in ALDH1A1 activity are associated with such diverse diseases as cancer, Parkinson's disease, obesity, and cataracts. Inhibitors of ALDH1A1 could aid in illuminating the role of this enzyme in disease processes. However, there are no commercially available selective inhibitors for ALDH1A1. Here we characterize two distinct chemical classes of inhibitors that are selective for human ALDH1A1 compared to eight other ALDH isoenzymes. The prototypical members of each structural class, CM026 and CM037, exhibit submicromolar inhibition constants but have different mechanisms of inhibition. The crystal structures of these compounds bound to ALDH1A1 demonstrate that they bind within the aldehyde binding pocket of ALDH1A1 and exploit the presence of a unique glycine residue to achieve their selectivity. These two novel and selective ALDH1A1 inhibitors may serve as chemical tools to better understand the contributions of ALDH1A1 to normal biology and to disease states.
    MeSH term(s) Aldehyde Dehydrogenase/antagonists & inhibitors ; Aldehyde Dehydrogenase/deficiency ; Aldehyde Dehydrogenase/genetics ; Aldehyde Dehydrogenase/metabolism ; Animals ; Dose-Response Relationship, Drug ; Enzyme Inhibitors/chemical synthesis ; Enzyme Inhibitors/chemistry ; Enzyme Inhibitors/classification ; Enzyme Inhibitors/pharmacology ; Humans ; Isoenzymes/antagonists & inhibitors ; Isoenzymes/metabolism ; Mice ; Mice, Knockout ; Models, Molecular ; Molecular Structure ; Structure-Activity Relationship
    Chemical Substances Enzyme Inhibitors ; Isoenzymes ; ALDH1A1 protein, human (EC 1.2.1.3) ; Aldehyde Dehydrogenase (EC 1.2.1.3)
    Language English
    Publishing date 2015-02-10
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, U.S. Gov't, Non-P.H.S.
    ZDB-ID 218133-2
    ISSN 1520-4804 ; 0022-2623
    ISSN (online) 1520-4804
    ISSN 0022-2623
    DOI 10.1021/jm501900s
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Development of a high-throughput in vitro assay to identify selective inhibitors for human ALDH1A1.

    Morgan, Cynthia A / Hurley, Thomas D

    Chemico-biological interactions

    2014  Volume 234, Page(s) 29–37

    Abstract: The human aldehyde dehydrogenase (ALDH) superfamily consists of at least 19 enzymes that metabolize endogenous and exogenous aldehydes. Currently, there are no commercially available inhibitors that target ALDH1A1 but have little to no effect on the ... ...

    Abstract The human aldehyde dehydrogenase (ALDH) superfamily consists of at least 19 enzymes that metabolize endogenous and exogenous aldehydes. Currently, there are no commercially available inhibitors that target ALDH1A1 but have little to no effect on the structurally and functionally similar ALDH2. Here we present the first human ALDH1A1 structure, as the apo-enzyme and in complex with its cofactor NADH to a resolution of 1.75 and 2.1Å, respectfully. Structural comparisons of the cofactor binding sites in ALDH1A1 with other closely related ALDH enzymes illustrate a high degree of similarity. In order to minimize discovery of compounds that inhibit both isoenzymes by interfering with their conserved cofactor binding sites, this study reports the use of an in vitro, NAD(+)-independent, esterase-based high-throughput screen (HTS) of 64,000 compounds to discover novel, selective inhibitors of ALDH1A1. We describe 256 hits that alter the esterase activity of ALDH1A1. The effects on aldehyde oxidation of 67 compounds were further analyzed, with 30 selectively inhibiting ALDH1A1 compared to ALDH2 and ALDH3A1. One compound inhibited ALDH1A1 and ALDH2, while another inhibited ALDH1A1, ALDH2, and the more distantly related ALDH3A1. The results presented here indicate that this in vitro enzyme activity screening protocol successfully identified ALDH1A1 inhibitors with a high degree of isoenzyme selectivity. The compounds identified via this screen plus the screening methodology itself represent a starting point for the development of highly potent and selective inhibitors of ALDH1A1 that may be utilized to better understand the role of this enzyme in both normal and disease states.
    MeSH term(s) Aldehyde Dehydrogenase/antagonists & inhibitors ; Enzyme Inhibitors/chemistry ; Enzyme Inhibitors/metabolism ; Esterases/metabolism ; High-Throughput Screening Assays/methods ; Humans ; In Vitro Techniques/methods ; Isoenzymes/metabolism ; NAD/metabolism
    Chemical Substances Enzyme Inhibitors ; Isoenzymes ; NAD (0U46U6E8UK) ; ALDH1A1 protein, human (EC 1.2.1.3) ; Aldehyde Dehydrogenase (EC 1.2.1.3) ; Esterases (EC 3.1.-)
    Language English
    Publishing date 2014-11-04
    Publishing country Ireland
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 218799-1
    ISSN 1872-7786 ; 0009-2797
    ISSN (online) 1872-7786
    ISSN 0009-2797
    DOI 10.1016/j.cbi.2014.10.028
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article: Genes encoding enzymes involved in ethanol metabolism.

    Hurley, Thomas D / Edenberg, Howard J

    Alcohol research : current reviews

    2012  Volume 34, Issue 3, Page(s) 339–344

    Abstract: The effects of beverage alcohol (ethanol) on the body are determined largely by the rate at which it and its main breakdown product, acetaldehyde, are metabolized after consumption. The main metabolic pathway for ethanol involves the enzymes alcohol ... ...

    Abstract The effects of beverage alcohol (ethanol) on the body are determined largely by the rate at which it and its main breakdown product, acetaldehyde, are metabolized after consumption. The main metabolic pathway for ethanol involves the enzymes alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH). Seven different ADHs and three different ALDHs that metabolize ethanol have been identified. The genes encoding these enzymes exist in different variants (i.e., alleles), many of which differ by a single DNA building block (i.e., single nucleotide polymorphisms [SNPs]). Some of these SNPs result in enzymes with altered kinetic properties. For example, certain ADH1B and ADH1C variants that are commonly found in East Asian populations lead to more rapid ethanol breakdown and acetaldehyde accumulation in the body. Because acetaldehyde has harmful effects on the body, people carrying these alleles are less likely to drink and have a lower risk of alcohol dependence. Likewise, an ALDH2 variant with reduced activity results in acetaldehyde buildup and also has a protective effect against alcoholism. In addition to affecting drinking behaviors and risk for alcoholism, ADH and ALDH alleles impact the risk for esophageal cancer.
    MeSH term(s) Acetaldehyde ; Alcohol Dehydrogenase ; Alcoholism/genetics ; Aldehyde Dehydrogenase ; Ethanol/metabolism ; Humans
    Chemical Substances Ethanol (3K9958V90M) ; Alcohol Dehydrogenase (EC 1.1.1.1) ; Aldehyde Dehydrogenase (EC 1.2.1.3) ; Acetaldehyde (GO1N1ZPR3B)
    Language English
    Publishing date 2012-11-06
    Publishing country United States
    Document type Editorial
    ISSN 2168-3492
    ISSN 2168-3492
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: The structural mechanism of human glycogen synthesis by the GYS1-GYG1 complex.

    Fastman, Nathan M / Liu, Yuxi / Ramanan, Vyas / Merritt, Hanne / Ambing, Eileen / DePaoli-Roach, Anna A / Roach, Peter J / Hurley, Thomas D / Mellem, Kevin T / Ullman, Julie C / Green, Eric / Morgans, David / Tzitzilonis, Christos

    Cell reports

    2022  Volume 40, Issue 1, Page(s) 111041

    Abstract: Glycogen is the primary energy reserve in mammals, and dysregulation of glycogen metabolism can result in glycogen storage diseases (GSDs). In muscle, glycogen synthesis is initiated by the enzymes glycogenin-1 (GYG1), which seeds the molecule by ... ...

    Abstract Glycogen is the primary energy reserve in mammals, and dysregulation of glycogen metabolism can result in glycogen storage diseases (GSDs). In muscle, glycogen synthesis is initiated by the enzymes glycogenin-1 (GYG1), which seeds the molecule by autoglucosylation, and glycogen synthase-1 (GYS1), which extends the glycogen chain. Although both enzymes are required for proper glycogen production, the nature of their interaction has been enigmatic. Here, we present the human GYS1:GYG1 complex in multiple conformations representing different functional states. We observe an asymmetric conformation of GYS1 that exposes an interface for close GYG1 association, and propose this state facilitates handoff of the GYG1-associated glycogen chain to a GYS1 subunit for elongation. Full activation of GYS1 widens the GYG1-binding groove, enabling GYG1 release concomitant with glycogen chain growth. This structural mechanism connecting chain nucleation and extension explains the apparent stepwise nature of glycogen synthesis and suggests distinct states to target for GSD-modifying therapeutics.
    MeSH term(s) Glucosyltransferases/metabolism ; Glycogen/metabolism ; Glycogen Synthase/metabolism ; Glycogenolysis ; Glycoproteins/metabolism ; Humans
    Chemical Substances Glycoproteins ; glycogenin ; Glycogen (9005-79-2) ; Glucosyltransferases (EC 2.4.1.-) ; Glycogen Synthase (EC 2.4.1.11)
    Language English
    Publishing date 2022-07-03
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2649101-1
    ISSN 2211-1247 ; 2211-1247
    ISSN (online) 2211-1247
    ISSN 2211-1247
    DOI 10.1016/j.celrep.2022.111041
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: A Novel ALDH1A1 Inhibitor Blocks Platinum-Induced Senescence and Stemness in Ovarian Cancer.

    Muralikrishnan, Vaishnavi / Fang, Fang / Given, Tyler C / Podicheti, Ram / Chtcherbinine, Mikhail / Metcalfe, Tara X / Sriramkumar, Shruthi / O'Hagan, Heather M / Hurley, Thomas D / Nephew, Kenneth P

    Cancers

    2022  Volume 14, Issue 14

    Abstract: Ovarian cancer is a deadly disease attributed to late-stage detection as well as recurrence and the development of chemoresistance. Ovarian cancer stem cells (OCSCs) are hypothesized to be largely responsible for the emergence of chemoresistant tumors. ... ...

    Abstract Ovarian cancer is a deadly disease attributed to late-stage detection as well as recurrence and the development of chemoresistance. Ovarian cancer stem cells (OCSCs) are hypothesized to be largely responsible for the emergence of chemoresistant tumors. Although chemotherapy may initially succeed at decreasing the size and number of tumors, it leaves behind residual malignant OCSCs. In this study, we demonstrate that aldehyde dehydrogenase 1A1 (ALDH1A1) is essential for the survival of OCSCs. We identified a first-in-class ALDH1A1 inhibitor, compound
    Language English
    Publishing date 2022-07-15
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2527080-1
    ISSN 2072-6694
    ISSN 2072-6694
    DOI 10.3390/cancers14143437
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Discovery of a series of aromatic lactones as ALDH1/2-directed inhibitors.

    Buchman, Cameron D / Mahalingan, Krishna K / Hurley, Thomas D

    Chemico-biological interactions

    2015  Volume 234, Page(s) 38–44

    Abstract: In humans, the aldehyde dehydrogenase superfamily consists of 19 isoenzymes which mostly catalyze the NAD(P)(+)-dependent oxidation of aldehydes. Many of these isoenzymes have overlapping substrate specificities and therefore their potential ... ...

    Abstract In humans, the aldehyde dehydrogenase superfamily consists of 19 isoenzymes which mostly catalyze the NAD(P)(+)-dependent oxidation of aldehydes. Many of these isoenzymes have overlapping substrate specificities and therefore their potential physiological functions may overlap. Thus the development of new isoenzyme-selective probes would be able to better delineate the function of a single isoenzyme and its individual contribution to the metabolism of a particular substrate. This specific study was designed to find a novel modulator of ALDH2, a mitochondrial ALDH isoenzyme most well-known for its role in acetaldehyde oxidation. 53 compounds were initially identified to modulate the activity of ALDH2 by a high-throughput esterase screen from a library of 63,000 compounds. Of these initial 53 compounds, 12 were found to also modulate the oxidation of propionaldehyde by ALDH2. Single concentration measurements at 10μM compound were performed using ALDH1A1, ALDH1A2, ALDH1A3, ALDH2, ALDH1B1, ALDH3A1, ALDH4A1, and/or ALDH5A1 to determine the selectivity of these 12 compounds toward ALDH2. Four of the twelve compounds shared an aromatic lactone structure and were found to be potent inhibitors of the ALDH1/2 isoenzymes, but have no inhibitory effect on ALDH3A1, ALDH4A1 or ALDH5A1. Two of the aromatic lactones show selectivity within the ALDH1/2 class, and one appears to be selective for ALDH2 compared to all other isoenzymes tested.
    MeSH term(s) Acetaldehyde/metabolism ; Aldehyde Dehydrogenase/antagonists & inhibitors ; Aldehyde Dehydrogenase/metabolism ; Aldehyde Dehydrogenase, Mitochondrial ; Aldehydes/metabolism ; Humans ; Isoenzymes/antagonists & inhibitors ; Isoenzymes/metabolism ; Lactones/metabolism ; Mitochondria/metabolism ; NADP/metabolism ; Oxidation-Reduction ; Retinal Dehydrogenase/antagonists & inhibitors ; Retinal Dehydrogenase/metabolism ; Substrate Specificity
    Chemical Substances Aldehydes ; Isoenzymes ; Lactones ; NADP (53-59-8) ; propionaldehyde (AMJ2B4M67V) ; aldehyde dehydrogenase 1 (EC 1.2.1.-) ; ALDH2 protein, human (EC 1.2.1.3) ; Aldehyde Dehydrogenase (EC 1.2.1.3) ; Aldehyde Dehydrogenase, Mitochondrial (EC 1.2.1.3) ; Retinal Dehydrogenase (EC 1.2.1.36) ; Acetaldehyde (GO1N1ZPR3B)
    Language English
    Publishing date 2015-06-05
    Publishing country Ireland
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 218799-1
    ISSN 1872-7786 ; 0009-2797
    ISSN (online) 1872-7786
    ISSN 0009-2797
    DOI 10.1016/j.cbi.2014.12.038
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top